E
KNTE

Ergoteles’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Ergoteles’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,060
Closed -$215K – 2093
2022
Q1 		$215K Buy
+19,060
New +$210K 0.01% 964

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ergoteles's KNTE Position: Q2 2022 in Review

Ergoteles sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2022, closing a stake of 19,060 shares — an estimated $215K sold.

Ergoteles first reported a position in KNTE in Q1 2022 and held it in 1 quarter. The position peaked at $215K in Q1 2022. 73 funds tracked by Wall St. Rank hold KNTE as of Q2 2022.

  • Ergoteles reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ergoteles sold 19,060 Kinnate Biopharma Inc. Common Stock shares in Q2 2022, an estimated $215K.
  • Ergoteles first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Ergoteles's Kinnate Biopharma Inc. Common Stock position peaked at $215K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.